Login to Your Account



ALSO HALTS INDIRECT AMPK PROGRAM

Rigel Pharmaceuticals scratches dry eye candidate and focuses on fostamatinib

By Marie Powers
Staff Writer

Thursday, August 14, 2014
Rigel Pharmaceuticals Inc. left open the tiniest prospect for success for dry eye candidate R348 after the Janus kinase/spleen tyrosine kinase (JAK/SYK) inhibitor missed both primary and secondary endpoints in a phase II study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription